BLOG

biopharma-reporter

Inhaled mAb therapy against COVID-19 in the works: ‘The product is not dependent on cold chain distribution and storage’

Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.